ACRS: Aclaris Therapeutics, Inc. Stock

by  •  • Comments Off on ACRS: Aclaris Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 121.95
Enterprise Value ($M) 97.38
Book Value ($M) 155.55
Book Value / Share 1.44
Price / Book 0.78
NCAV ($M) 61.18
NCAV / Share 0.57
Price / NCAV 1.99

Profitability (mra)
Return on Invested Capital (ROIC) -0.84
Return on Assets (ROA) -0.76
Return on Equity (ROE) -0.93

Liquidity (mrq)
Quick Ratio 3.99
Current Ratio 3.99

Balance Sheet (mrq) ($M)
Current Assets 125.95
Assets 220.33
Liabilities 64.77
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 18.72
Operating Income -52.53
Net Income -132.06
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -20.07
Cash from Investing -69.77
Cash from Financing 74.54

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A BML Investment Partners, L.P. 13.30 51.66
02-12 13G Adage Capital Management, L.P. 9.00
11-25 13G Biosion, Inc. 9.50
11-22 13G Rock Springs Capital Management LP 6.32 125.51
11-21 13G Vivo Opportunity Fund Holdings, L.P. 7.40
11-14 13G/A Citadel Advisors Llc 0.50
10-09 13G/A Millennium Management Llc 4.20 -20.27
07-08 13G/A BlackRock, Inc. 2.90 -65.59

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2024-11-06 10-Q 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-07 10-Q 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-07 10-Q 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 76,038 513,588 14.81
2025-04-16 36,641 712,147 5.15
2025-04-15 45,754 444,717 10.29
2025-04-14 107,178 694,762 15.43

(click for more detail)

Similar Companies
ABUS – Arbutus Biopharma Corporation ACAD – ACADIA Pharmaceuticals Inc.
ACLX – Arcellx, Inc. ACT – Enact Holdings, Inc.
ADPT – Adaptive Biotechnologies Corporation


Financial data and stock pages provided by
Fintel.io